Cargando…
Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4(+) Cell Rises in HIV-Infected Patients
BACKGROUND: Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. We investigated whether this is due to modulation of T cell activation and inflammation. METHODS AND FINDINGS: Thirty maraviroc-treated patients fr...
Autores principales: | Funderburg, Nicholas, Kalinowska, Magdalena, Eason, James, Goodrich, James, Heera, Jayvant, Mayer, Howard, Rajicic, Natasa, Valdez, Hernan, Lederman, Michael M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950842/ https://www.ncbi.nlm.nih.gov/pubmed/20949133 http://dx.doi.org/10.1371/journal.pone.0013188 |
Ejemplares similares
-
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
por: Cooper, David A., et al.
Publicado: (2014) -
Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
por: Gulick, Roy M., et al.
Publicado: (2014) -
The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014) -
First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN
por: Heera, Jayvant, et al.
Publicado: (2014) -
Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program
por: Lazzarin, A, et al.
Publicado: (2010)